NCT03220035
NCI-COG Pediatric MATCH (Molecular Analysis for Therapy Choice) - Phase 2 Subprotocol of Vemurafenib in Patients with Tumors Harboring BRAF V600 Mutations
Associated Conditions
Cancer, All Tumor TypesSponsor
Children's Oncology Group
You are being asked to participate in this study because you have relapsed or refractory tumor without a proven treatment strategy for cure. The main goal is to test any good and bad effects of the study drug vemurafenib on your tumor. A second goal of the study is to evaluate side effects that might be caused by vemurafenib.